Evidence map›Paper›PMID 38772578›Full record

ArticleBMJ open2024

Protocol for a pragmatic randomised controlled feasibility study of

Ingrid van der Mei, Sarah Thomas, Sue Shapland, Laura L Laslett, Bruce V Taylor, Alisée Huglo, Cynthia Honan

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ingrid van der MeiMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia ingrid.vandermei@utas.edu.au.ORCID 0000-0001-9009-7472
Sarah ThomasFaculty of Health and Social Sciences, Bournemouth University, Poole, UK.ORCID 0000-0002-9501-9091
Sue ShaplandMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Laura L LaslettMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Bruce V TaylorMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.ORCID 0000-0003-2807-0070
Alisée HugloMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Cynthia HonanSchool of Psychological Sciences, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMultiple sclerosis (MS) causes a wide variety of symptoms. Loss of income due to sickness and early retirement comprise one-third of the total cost of MS in Australia. An intervention that maximises work productivity and keeps people with MS in the workforce for longer could provide a large societal cost saving and improve quality of life. The aim is to test the feasibility of delivering and evaluating a 10-week digitally delivered intervention called ' METHODS AND ANALYSIS: A parallel-arm randomised controlled feasibility study, comparing those randomised to receive the MS WorkSmart package plus usual care (n=20) to those receiving usual care only (n=20). Australians with MS, aged 18-60 years, who are employed, and self-report work instability will be recruited from the Australian MS Longitudinal Study. Online surveys, at baseline and 1-month postintervention, will include MS-related work productivity loss and risk of job loss, MS work behaviour self-efficacy, health-related quality of life, fatigue severity, MS symptom impact on work, intention to retire due to MS, MS-related work difficulties, and awareness and readiness for change at work. Qualitative feedback will be obtained via a semistructured survey following the intervention (for participants) and via interviews (coaches). Analyses will be primarily descriptive and focus on the feasibility and acceptability of the intervention and study procedures. Progression criteria will guide decisions around whether to progress to a full trial. ETHICS AND DISSEMINATION: The study has been approved by the University of Tasmania Human Research Ethics Committee (H0024544). Findings will be disseminated via publication in peer-reviewed journals, conference presentations and community presentations. TRIAL REGISTRATION NUMBER: ACTRN12622000826741.

Indexed as

EmploymentFeasibility StudiesMultiple SclerosisQuality of LifeAdolescentAdultAustralasian PeopleAustraliaEfficiencyFemaleHumansInternet-Based InterventionMaleMiddle AgedPragmatic Clinical Trials as TopicRandomized Controlled Trials as Topicfeasibility studiesmultiple sclerosisrandomized controlled trial

Identifiers

PMID38772578
PMCPMC11110555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.